Search Results

You are looking at 111 - 120 of 576 items for :

  • Refine by Access: All x
Clear All
Full access

CLO22-065: Treatment Failure and Transition to Next-Line Therapy in Myelofibrosis: A Modified Delphi Panel Approach

John Mascarenhas, Arianna Kee, Hiep Nguyen, Ashley Saunders, Louisa Oliver, Hannah Tomkinson, Richard Perry, and Ali McBride

consensus statements suggest patient-reported symptoms of fatigue, poor concentration, inactivity, and bone pain were too general to define RUX failure compared with other specific MF symptoms ie, night sweats. Following RUX failure, consensus

Full access

CLO22-056: Phase I Trial of Concurrent Nab-paclitaxel and Cisplatin With Radiotherapy for Locally Advanced Cervical Cancer

Ping Jiang, Ang Qu, Weijuan Jiang, Xiuwen Deng, and Junjie Wang

twice a week. Dose escalation followed a 3 + 3 design. The DLT was defined as grade 3 or 4 nonhematologic toxicity, excluding nausea, vomiting and alopecia, decreased appetite and fatigue, or grade 4 hematologic toxicity. Results : This study was

Full access

HSR20-076: Provider Versus Patient Reported Outcomes (PROs) in Colorectal Cancer (CRC) Patients (pts) Undergoing Systemic Therapy (Ctx): A Real World Experience

Sonali Agrawal, Caitlin R. Meeker, Sandeep Aggarwal, Elizabeth A. Handorf, Sunil Adige, Efrat Dotan, Crystal S. Denlinger, William H. Ward, Jeffrey M. Farma, and Namrata Vijayvergia

(others were on clinical trials with novel agents). Most common grade 3+ tox reported by providers included nausea (10%) and neuropathy (8%), while the common clinically significant tox reported by pts were neuropathy (20%), fatigue (20%), and anxiety (15

Full access

Communicating About Chemotherapy-Induced Nausea and Vomiting: A Comparison of Patient and Provider Perspectives

John M. Salsman, Steven M. Grunberg, Jennifer L. Beaumont, Miriam Rogers, Diane Paul, Marla L. Clayman, and David Cella

, available online, in this article, at www.JNCCN.org ) Nausea and Vomiting Management Barriers Questionnaire (NVMBQ) were developed using the Fatigue Management Barriers Questionnaire (FMBQ) 16 as a template. Patient-related barriers to communicating about

Full access

Role of Adjuvant and Posttreatment Exercise Programs in Breast Health

Jennifer A. Ligibel

diagnosis have lower rates of recurrence and death compared with sedentary individuals. A growing number of exercise intervention studies show that increased physical activity after diagnosis leads to improvements in quality of life, fatigue, and body image

Full access

Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy

David D. Chism

-related AEs (TRAEs) included fatigue, pneumonitis, rash, and dyspnea. Among the 119 cisplatin-ineligible patients in cohort 1 who received atezolizumab in the first-line setting, there was an ORR of 23% (95% CI, 16–31) and a CR of 9%, with durable responses

Full access

Distress Screening and the Integration of Psychosocial Care Into Routine Oncologic Care

Jimmie C. Holland

-report was considered totally invalid,” explained Dr. Holland. To begin to measure subjective symptoms, validated, quantitative tools were developed in the 1970s and 1980s. Scales focused on items such as health-related quality of life, pain, fatigue

Full access

Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer

Philip E. Lammers and Leora Horn

show superiority. The toxicities differed between arms; more grade 3/4 thrombocytopenia (23.3% vs 5.6%), anemia (14.5% vs 2.7%), and fatigue (10.9% vs 5.0%) were seen in the pemetrexed group, whereas more grade 3/4 neutropenia (40.6% vs 25.8%), febrile

Full access

The NCCN 2023 Annual Conference

and suggested approaches that can improve inclusion and equity in oncology. In another plenary session focused on sleep disorders, fatigue, and cognitive function in cancer survivors (synopsis available at JNCCN.org ) speakers again noted the need

Full access

New Meets Old: A Case Study and Review of Novel Therapeutics for the Treatment of CLL in Older Patients

Neel K. Gupta and Charalambos Andreadis

performed. He was asymptomatic, without palpable adenopathy or organomegaly, and was monitored expectantly during the next 5 years, remaining free of symptoms or hematologic abnormalities. By August 2009 he developed mild fatigue, cervical lymphadenopathy